BioAge Labs Advances Longevity Drug

BioAge's approach is centered on analyzing longitudinal human data to identify key molecular pathways that drive aging. The company's platform uses machine learning to analyze biobank samples from individuals over decades, searching for biological drivers of healthy longevity that can be targeted with new drugs. This data-driven strategy led them to the NLRP3 inflammasome, a key component of the immune system implicated in age-related inflammation. BGE-102 is an orally available small molecule designed to inhibit the NLRP3 inflammasome. In a Phase 1 trial, the drug was well-tolerated and demonstrated high brain penetration. Data from a cohort of participants with obesity and elevated inflammation showed that a 120 mg daily dose of BGE-102 led to an 86% median reduction in high-sensitivity C-reactive protein (hsCRP), a key marker of cardiovascular risk, after 14 days. The global market for NLRP3 inflammasome inhibitors was valued at $1.12 billion in 2024 and is projected to grow to $5.43 billion by 2033. This growth is driven by the role of NLRP3 in a wide range of conditions, including autoimmune, cardiovascular, and neurodegenerative diseases. More than 20 companies are actively developing over 25 different NLRP3 inhibitor drug candidates. BioAge, co-founded by CEO Kristen Fortney, Ph.D., and COO Eric Morgen, M.D., has raised a total of $294 million over four funding rounds. The company went public in September 2024. Its investors include Andreessen Horowitz, Sofinnova Investments, and Amgen's venture arm. In addition to its internal discovery programs, BioAge actively pursues partnerships. In December 2024, the company announced a multi-year collaboration with Novartis worth up to $550 million to discover new therapeutic targets related to aging and exercise biology. The company is also expanding the development of BGE-102 into ophthalmology, with a trial for diabetic macular edema planned for mid-2026. The longevity biotech industry is gaining significant traction, with startups attracting $8.5 billion in venture capital in 2024 alone. This sector focuses on targeting the fundamental mechanisms of aging to prevent or treat chronic diseases. Other approaches in the field include cellular rejuvenation, senolytics (drugs that clear aging "zombie" cells), and epigenetic reprogramming. Initially, BGE-102 was being developed for obesity, with preclinical models showing weight loss comparable to semaglutide. The company has since pivoted to focus on cardiovascular risk factors and other inflammation-driven diseases. This strategic shift followed the discontinuation of a different obesity drug, azelaprag, in late 2024 due to liver-related safety concerns. BioAge's core strategy involves leveraging its AI-driven platform and human longevity data to build a pipeline of drugs targeting various aspects of aging. Besides the NLRP3 inhibitor BGE-102, the company is also developing APJ agonists for obesity. This "pipeline in a pill" approach aims to address multiple age-related diseases with a single therapeutic.